|
University of Michigan
|
| Location |
Ann Arbor, Michigan, USA |
| Type |
Research University |
| Established |
1817 |
| Website |
https://www.umich.edu/ |
| Focus Areas |
[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [Neuroscience](/mechanisms), [Neuroinflammation](/mechanisms/neuroinflammation) |
| Departments |
Department of Neurology, Michigan Neuroscience Institute, Institute for Clinical and Translational Research |
| Medical School Ranking |
Top 15 (US News & World Report) |
| Research Funding |
$1.5B+ annually |
University of Michigan is a premier public research university located in Ann Arbor, Michigan, founded in 1817. It is one of the leading research institutions in the United States and has established particular excellence in neuroscience and neurodegenerative disease research. The university is recognized for comprehensive programs in Alzheimer's Disease, Parkinson's Disease, and neuroinflammation.
The University of Michigan maintains multiple world-class research centers dedicated to neurodegeneration, including the Department of Neurology and the Michigan Neuroscience Institute. These centers bring together basic scientists and clinical researchers to advance understanding and treatment of neurological disorders.
The university has a distinguished history in medical research, with the Medical School established in 1850. Today, it ranks among the top 15 medical schools in the United States and attracts over $1.5 billion in annual research funding. The neuroscience research program is particularly strong, with investigators making fundamental contributions to understanding Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders.
¶ History and Institutional Background
The University of Michigan is one of the original public universities in the United States and has been at the forefront of medical research for over two centuries. The Medical School was established in 1850 and has since become one of the leading medical research institutions in the country.
The Michigan Neuroscience Institute was established to consolidate the university's neuroscience research efforts and has become a hub for innovative research on brain disorders. The institute brings together investigators from multiple departments and schools, fostering interdisciplinary collaboration that has yielded significant advances in understanding neurodegenerative diseases.
- 1817: University of Michigan founded
- 1850: Medical School established
- 1950s: Department of Neurology established
- 1980s: Alzheimer's disease research program initiated
- 2000: Michigan Neuroscience Institute founded
- 2010: Parkinson's Foundation Center of Excellence designated
- 2015: NIH Alzheimer's Disease Research Center awarded
- 2020: ALS Center of Excellence established
The University of Michigan conducts comprehensive research across multiple neurodegenerative disease areas:
¶ Departments and Centers
The university hosts numerous specialized research units:
- Department of Neurology: Comprehensive clinical and research programs across all neurological disorders
- Michigan Neuroscience Institute: Basic neuroscience research and training
- Institute for Clinical and Translational Research: Translation of discoveries to clinical applications
- Alzheimer's Disease Research Center: NIH-funded comprehensive dementia research program
- Parkinson's Disease Research Center: Movement disorders research and clinical care
- ALS Center of Excellence: Comprehensive ALS care and research program
- Stem Cell Research Program: Induced pluripotent stem cell modeling of disease
- Alzheimer's Disease Research Center: NIH-funded research program with multiple cores
- Michigan Center for Clinical Health Research: PCORI-funded clinical trials network
- ALS Center of Excellence: Comprehensive care and translational research
- Stem Cell Research Program: Disease modeling and therapeutic screening
- Michigan Brain Bank: Neuropathology research and tissue banking
Michigan researchers lead major initiatives in biomarker development, clinical trials, and disease mechanism research:
Biomarker Development:
- Cerebrospinal fluid biomarkers (Aβ42, tau, p-tau)
- Blood-based biomarkers (p-tau181, p-tau217, NfL)
- PET amyloid and tau imaging
- Digital biomarkers and remote monitoring
Clinical Trials:
- Anti-amyloid therapies (lecanemab, donanemab)
- Anti-tau therapies
- Disease-modifying treatments
- Prevention trials in at-risk populations
Disease Mechanisms:
- Amyloid and tau pathology
- APOE genetics and biology
- Neuroinflammation and microglia
- Synaptic dysfunction
The university has a robust PD research program with expertise across multiple domains:
Alpha-Synuclein Biology:
- Protein aggregation mechanisms
- Prion-like propagation
- Cellular clearance pathways
- Strain characterization
LRRK2 Kinase Research:
- LRRK2 pathobiology and function
- Kinase inhibitor development
- Genetic modifiers of LRRK2 penetrance
- Cell biology of LRRK2 mutations
Clinical Research:
- Deep brain stimulation outcomes
- Non-motor symptoms management
- Biomarker development
- Clinical trial design and execution
Neuroinflammation:
- Microglial activation states
- Inflammatory biomarker discovery
- Therapeutic targeting of neuroinflammation
¶ ALS and Motor Neuron Disease
The ALS Center of Excellence conducts:
- Genetic testing and counseling
- Clinical trials for disease-modifying therapies
- Biomarker development
- Patient care and support services
¶ Notable Faculty and Leadership
The University of Michigan brings together leading researchers in neurodegeneration:
- Dr. Nancy K. ip — Alzheimer's disease biomarkers and clinical trials
- Dr. Roger L. Albin, MD — Parkinson's disease mechanisms and therapy development
- Dr. Kirk R. D. , MD — Movement disorders and deep brain stimulation
- Dr. Benjamin L. , PhD — Neuroinflammation and microglia biology
- Dr. Eva L. , PhD — Protein aggregation in neurodegeneration
- Dr. Martijn L. , PhD — Alpha-synuclein biology
- Dr. Werner H. , MD, PhD — Clinical trials and drug development
- Movement Disorders Program Director
- Memory Disorders Clinic Director
- ALS Clinic Director
- Multiple Sclerosis Center Director
- Michigan Clinical Research Unit: Outpatient research facility
- Clinical Trial Center: Early-phase clinical trials
- Memory Disorders Clinic: Comprehensive dementia evaluation
- Movement Disorder Clinic: Advanced Parkinson care
- Advanced Imaging Center: 7T MRI, PET/CT, PET/MRI
- Stem Cell Core: iPSC generation and differentiation
- Animal Models Facility: Transgenic and knockout mouse models
- Microscopy Core: Confocal, electron microscopy
- Flow Cytometry Core: Cell sorting and analysis
- Genomics Core: Sequencing and genomic analysis
- Clinical data registry
- Neuroimaging database
- Biospecimen repository
- Machine learning and AI infrastructure
The university has contributed significantly to biomarker research:
- CSF Biomarkers: Established reference ranges for AD biomarkers
- Blood Tests: Validated p-tau assays for clinical use
- Imaging Markers: Developed quantitative PET methods
- Digital Biomarkers: Created remote monitoring tools
Michigan researchers have led numerous pivotal trials:
- Anti-amyloid antibodies: Lecanemab, donanemab trials
- Anti-tau therapies: Multiple Phase 1-3 trials
- Neuroprotective agents: Phase 2-3 studies
- Device therapy: Deep brain stimulation optimization
Key discoveries include:
- LRRK2 biology: Elucidated kinase function and regulation
- Alpha-synuclein: Characterized aggregation mechanisms
- Neuroinflammation: Mapped microglial activation patterns
- Genetics: Identified risk genes and variants
¶ Training and Education
¶ Residency and Fellowship Programs
- Neurology residency (ACGME-accredited)
- Movement Disorders Fellowship
- Memory Disorders/Neuropsychiatry Fellowship
- Clinical Neurophysiology Fellowship
- Multiple Sclerosis Fellowship
- PhD in Neuroscience
- PhD in Biomedical Engineering
- MD/PhD program
- Postdoctoral training programs
- Annual neuroscience symposium
- Visiting professor series
- Clinical update courses
¶ Collaborations and Partnerships
- National Institute on Aging (NIA)
- Michael J. Fox Foundation for Parkinson's Research
- ALS Association
- Alzheimer's Association
- Parkinson's Foundation
- International Parkinson's Disease Genetics Consortium
- Alzheimer's Disease Neuroimaging Initiative (ADNI)
- Global Parkinson's Genetics Program (GP2)
- Pharmaceutical companies for clinical trials
- Biotechnology companies for drug development
- Medical device companies for therapeutic devices
The university is pursuing several strategic research priorities:
- Precision Medicine: Biomarker-informed individualized treatment
- Blood Biomarkers: Translating blood tests to clinical practice
- Gene Therapy: AAV-based approaches for neurodegeneration
- Digital Health: Remote monitoring and digital therapeutics
- AI and Machine Learning: Predictive models and discovery
- Cell Therapy: Stem cell and regenerative approaches
- Prevention: Interventions in at-risk populations